Digital health company UpDoc has received FDA clearance for a diabetes management app that uses patient-facing large language models — believed to be the first such clearance for medical software in this category. The app, cleared in December 2025, helps health systems manage patients outside the clinic with AI-supported guidance.
The device operates in the same regulatory category as insulin dose calculators, taking inputs like blood glucose levels and returning treatment recommendations. What sets it apart is a chatbot-like LLM interface that accepts voice and text input and responds with treatment instructions aligned to a physician-defined plan. The system also communicates back to the doctor’s electronic health record.
The clearance has sparked debate in the regulatory community. STAT News reported that UpDoc’s CEO would not clarify whether the generative AI component makes independent treatment decisions or simply serves as an interface layer over rule-based clinical logic, raising unresolved questions about how FDA evaluates LLM-enabled medical devices.
